Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Marcus

Showing results (151-160 of 230) with videos related to

Pageof 23
Sort By:
SAGE Open|January 7, 2020
Clinical Encounters and Treatment Initiation for Chronic Hepatitis C Patients: Applications of Adaptive Leadership Framework for Chronic IllnessDonald E Bailey, Andrew J Muir, Judith A Adams, et al.
Psychopharmacology|September 6, 2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidolRaisa Andrezina, Richard C Josiassen, Ronald N Marcus, et al.
The Journal of Comparative Neurology|May 23, 2001
Differential expression of orexin receptors 1 and 2 in the rat brainJ N Marcus, C J Aschkenasi, C E Lee, et al.
The Journal of Clinical Psychiatry|August 5, 2011
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter studyRonald N Marcus, Randall Owen, George Manos, et al.
The Journal of Clinical Psychiatry|June 27, 2007
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyRobert M Berman, Ronald N Marcus, René Swanink, et al.
Neurobiology of Aging|July 5, 2021
Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial inductionRenee C Gentzel, Dawn Toolan, Sarah Jinn, et al.
Joint Commission Journal on Quality and Patient Safety|February 9, 2025
Using Implementation Science-Informed Strategies to Improve Transitions of Care for Patients with Venous ThromboembolismElizabeth L Ciemins, Cori C Grant, Meghana Tallam, et al.
The Journal of Clinical Psychiatry|January 1, 1996
The safety profile of nefazodoneD S Robinson, D L Roberts, J M Smith, et al.
International Journal of Clinical Practice|April 1, 2008
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled studyD J Muzina, C Momah, J M Eudicone, et al.
Breast Cancer Research and Treatment|July 1, 1997
BRCA2 hereditary breast cancer pathophenotypeJ N Marcus, P Watson, D L Page, et al.
Pageof 23

Showing results (151-160 of 230) with videos related to

Sort By:
Pageof 23
SAGE Open|January 7, 2020
Clinical Encounters and Treatment Initiation for Chronic Hepatitis C Patients: Applications of Adaptive Leadership Framework for Chronic IllnessDonald E Bailey, Andrew J Muir, Judith A Adams, et al.
Psychopharmacology|September 6, 2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidolRaisa Andrezina, Richard C Josiassen, Ronald N Marcus, et al.
The Journal of Comparative Neurology|May 23, 2001
Differential expression of orexin receptors 1 and 2 in the rat brainJ N Marcus, C J Aschkenasi, C E Lee, et al.
The Journal of Clinical Psychiatry|August 5, 2011
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter studyRonald N Marcus, Randall Owen, George Manos, et al.
The Journal of Clinical Psychiatry|June 27, 2007
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyRobert M Berman, Ronald N Marcus, René Swanink, et al.
Neurobiology of Aging|July 5, 2021
Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial inductionRenee C Gentzel, Dawn Toolan, Sarah Jinn, et al.
Joint Commission Journal on Quality and Patient Safety|February 9, 2025
Using Implementation Science-Informed Strategies to Improve Transitions of Care for Patients with Venous ThromboembolismElizabeth L Ciemins, Cori C Grant, Meghana Tallam, et al.
The Journal of Clinical Psychiatry|January 1, 1996
The safety profile of nefazodoneD S Robinson, D L Roberts, J M Smith, et al.
International Journal of Clinical Practice|April 1, 2008
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled studyD J Muzina, C Momah, J M Eudicone, et al.
Breast Cancer Research and Treatment|July 1, 1997
BRCA2 hereditary breast cancer pathophenotypeJ N Marcus, P Watson, D L Page, et al.
Pageof 23